Prosight Management, LP holds a focused book of 46 stocks worth $609.8M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Alkermes PLC and trimmed Adc Therapeutics Sa. Their largest long position is Nektar Therapeutics at 9% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1617201/holdings"
Use Arkolith to show Prosight Management, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
98% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Nektar Therapeutics COM NEW | $52.9M | 735.0K | 8.7% | ▲+33% Added · +180K sh | |
| 2 | Boston Scientific Corp COM | $49.9M | 795.5K | 8.2% | ▲+279% Added · +586K sh | |
| 3 | Janux Therapeutics Inc COM | $49.3M | 3.55M | 8.1% | ▲+48% Added · +1.2M sh | |
| 4 | Procept Biorobotics Corp COM | $48.6M | 1.95M | 8.0% | ▲+41% Added · +565K sh | |
| 5 | Galapagos NV SPON ADR | $46.5M | 1.55M | 7.6% | ▲+44% Added · +476K sh | |
| 6 | Genedx Holdings Corp COM CL A | $33.6M | 523.5K | 5.5% | ▲+852% Added · +468K sh | |
| 7 | Shattuck Labs Inc COM | $32.2M | 5.00M | 5.3% | ▲+110% Added · +2.6M sh | |
| 8 | Adc Therapeutics Sa SHS | $31.1M | 8.30M | 5.1% | ▼−2.1% Reduced · −177K sh | |
| 9 | Kura Oncology Inc COM | $27.3M | 3.36M | 4.5% | ▲+33% Added · +827K sh | |
| 10 | Alnylam Pharmaceuticals Inc COM | $25.1M | 76.0K | 4.1% | ▲+344% Added · +59K sh | |
| 11 | Meiragtx Hldgs PLC COM | $22.8M | 2.63M | 3.7% | ▼−18% Reduced · −580K sh | |
| 12 | Alkermes PLC SHS | $18.2M | 513.6K | 3.0% | ▲New New position | |
| 13 | Syndax Pharmaceuticals Inc COM | $18.0M | 770.0K | 2.9% | ▲+16% Added · +105K sh | |
| 14 | Veeva Sys Inc CL A COM | $15.2M | 86.5K | 2.5% | ▼−4.0% Reduced · −4K sh | |
| 15 | Zymeworks Inc COM | $13.5M | 539.0K | 2.2% | ▲+1.6% Added · +9K sh | |
| 16 | Crinetics Pharmaceuticals In COM | $12.7M | 350.0K | 2.1% | ▲+33% Added · +87K sh | |
| 17 | Abivax Sa SPONSORED ADS | $11.7M | 105.0K | 1.9% | ▲+518% Added · +88K sh | |
| 18 | Concentra Group Holdings Par COMMON STOCK | $10.8M | 505.8K | 1.8% | ▼−43% Reduced · −385K sh | |
| 19 | Terns Pharmaceuticals Inc COM | $10.7M | 202.3K | 1.7% | ▲+113% Added · +107K sh | |
| 20 | Phreesia Inc COM | $9.2M | 1.10M | 1.5% | ▲+13% Added · +123K sh | |
| 21 | Onkure Therapeutics Inc COM CL A | $8.9M | 2.15M | 1.5% | ▲+164% Added · +1.3M sh | |
| 22 | Corbus Pharmaceuticals Hldgs COM NEW | $6.5M | 697.1K | 1.1% | ▲+1.9% Added · +13K sh | |
| 23 | Schrodinger Inc COM | $5.8M | 510.6K | 1.0% | ▲New New position | |
| 24 | Emergent Biosolutions Inc COM | $5.3M | 639.1K | 0.9% | ▲New New position | |
| 25 | Roivant Sciences Ltd SHS | $5.0M | 180.0K | 0.8% | ▼−71% Reduced · −447K sh | |
| 26 | Orthopediatrics Corp COM | $4.8M | 302.4K | 0.8% | ▲+121% Added · +166K sh | |
| 27 | Immunovant Inc COM | $4.4M | 175.8K | 0.7% | ▼−28% Reduced · −68K sh | |
| 28 | Icu Med Inc COM | $3.5M | 27.4K | 0.6% | ▲New New position | |
| 29 | Tectonic Therapeutic Inc COM | $2.5M | 79.9K | 0.4% | ▼−66% Reduced · −155K sh | |
| 30 | Rocket Pharmaceuticals Inc COM | $2.4M | 683.9K | 0.4% | ▼−8.1% Reduced · −60K sh | |
| 31 | Upstream Bio Inc COM | $2.2M | 241.1K | 0.4% | ▲New New position | |
| 32 | Pliant Therapeutics Inc COM | $2.1M | 1.67M | 0.3% | ▲+7.2% Added · +112K sh | |
| 33 | Omeros Corp COM | $1.8M | 174.8K | 0.3% | ▲New New position | |
| 34 | Intuitive Surgical Inc COM NEW | $1.8M | 4.0K | 0.3% | ▲New New position | |
| 35 | An2 Therapeutics Inc COM | $1.8M | 515.8K | 0.3% | ▲New New position | |
| 36 | Adicet Bio Inc COM NEW | $1.7M | 250.2K | 0.3% | —Held | |
| 37 | Regenxbio Inc COM | $1.7M | 200.0K | 0.3% | ▲New New position | |
| 38 | Coya Therapeutics Inc COMMON STOCK | $1.7M | 420.4K | 0.3% | ▲New New position | |
| 39 | Viking Therapeutics Inc COM | $1.5M | 45.0K | 0.2% | ▲New New position | |
| 40 | Irhythm Holdings Inc COM | $1.2M | 10.0K | 0.2% | ▲New New position | |
| 41 | Trueblue Inc COM | $974K | 249.1K | 0.2% | ▼−44% Reduced · −193K sh | |
| 42 | Immuneering Corp CLASS A COM | $650K | 123.4K | 0.1% | ▲New New position | |
| 43 | Palvella Therapeutics Inc Ne COM | $623K | 5.0K | 0.1% | ▲New New position | |
| 44 | Novocure Ltd ORD SHS | $549K | 50.4K | 0.1% | ▲New New position | |
| 45 | Rein Therapeutics Inc COM NEW | $535K | 411.6K | 0.1% | ▼−7.0% Reduced · −31K sh | |
| 46 | Transmedics Group Inc COM | $497K | 5.0K | 0.1% | ▲New New position |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.